Welcome to our dedicated page for Dare Bioscience news (Ticker: DARE), a resource for investors and traders seeking the latest updates and insights on Dare Bioscience stock.
Overview of Daré Bioscience Inc.
Daré Bioscience Inc. (NASDAQ: DARE) is a clinical-stage biopharmaceutical company dedicated to advancing innovative solutions in women’s health. With a mission to address significant unmet needs, Daré focuses on developing and bringing to market a diverse portfolio of differentiated therapies that prioritize women’s health and well-being. The company’s core areas of focus include contraception, sexual health, fertility, menopause, pelvic pain, and infectious diseases.
Business Model and Revenue Streams
Daré Bioscience operates through a strategic blend of partnerships, licensing agreements, and non-dilutive funding sources. The company collaborates with industry leaders like Bayer and Organon to commercialize its innovative products, leveraging these partnerships to expand market reach. Additionally, Daré secures grants and funding from organizations such as the Bill & Melinda Gates Foundation and ARPA-H to support the development of its pipeline products. This approach minimizes financial risk while advancing its mission to deliver groundbreaking therapies.
Product Portfolio
Daré’s product pipeline is centered around first-in-category candidates that address critical gaps in women’s health care:
- Ovaprene®: A hormone-free, monthly intravaginal contraceptive currently in advanced clinical trials. Licensed to Bayer for U.S. commercialization, Ovaprene represents a novel, non-hormonal option for contraception.
- Sildenafil Cream, 3.6%: An investigational topical cream for female sexual arousal disorder (FSAD), a condition analogous to erectile dysfunction in men. This product aims to be the first FDA-approved treatment for FSAD.
- XACIATO™: An FDA-approved vaginal gel for the treatment of bacterial vaginosis in females aged 12 and older, marketed in collaboration with Organon.
- DARE-HRT1: A combination bio-identical estradiol and progesterone intravaginal ring for menopausal hormone therapy, designed to address menopausal symptoms effectively.
- DARE-HPV: An investigational treatment for HPV-related cervical diseases, with the potential to be the first FDA-approved pharmaceutical intervention for both early and late-stage cervical lesions.
- DARE-LARC1: A long-acting, reversible contraceptive implant featuring wireless control and precision dosing, designed to provide extended contraceptive efficacy.
Market Position and Competitive Landscape
Daré Bioscience differentiates itself through its focus on women’s health, a historically underserved market segment. By addressing unmet needs with innovative, first-in-category products, the company positions itself as a key player in the biopharmaceutical industry. Strategic collaborations with global leaders like Bayer and Organon enhance its market reach and credibility. Despite challenges such as regulatory hurdles and competition from established pharmaceutical companies, Daré’s targeted approach and robust pipeline underscore its potential for significant impact in women’s health care.
Regulatory and Clinical Development
Daré’s product candidates undergo rigorous clinical trials to ensure safety and efficacy. For instance, Sildenafil Cream has completed a Phase 2b study demonstrating promising results for FSAD, and the company is preparing for Phase 3 trials. Similarly, Ovaprene is progressing through pivotal clinical studies, with FDA feedback shaping its development pathway. These efforts exemplify Daré’s commitment to meeting stringent regulatory standards while advancing innovative therapies.
Strategic Partnerships and Funding
Daré’s collaborations with organizations like Bayer, Organon, and Theramex play a pivotal role in its business strategy. These partnerships not only facilitate commercialization but also validate the company’s innovative approach. Additionally, non-dilutive funding from entities such as the Gates Foundation and ARPA-H supports the development of groundbreaking products, reducing financial risk and enabling sustained innovation.
Conclusion
Daré Bioscience Inc. is at the forefront of innovation in women’s health, addressing critical unmet needs with a robust pipeline of first-in-category products. Through strategic partnerships, rigorous clinical development, and a focus on underserved markets, the company is poised to make a significant impact in the biopharmaceutical industry.
Daré Bioscience (NASDAQ: DARE) announced the initiation of a Phase 1 clinical trial for DARE-PDM1, aimed at treating primary dysmenorrhea with a novel vaginal delivery system for diclofenac. This phase involves around 36 healthy premenopausal women to assess pharmacokinetics and safety, with the potential to provide a new treatment option in a market projected to grow from USD $13 billion in 2022 to USD $28.5 billion by 2029. DARE-PDM1 could become the first FDA-approved vaginal diclofenac product, enhancing pain relief while reducing systemic side effects associated with oral NSAIDs.
Daré Bioscience, a leader in women’s health innovation, announced participation in key February conferences. CEO Sabrina Martucci Johnson will present at the 2023 BIO CEO & Investor Conference from February 6-9, with a presentation scheduled for February 7 at 3:00 p.m. EST. The company will also be involved in the virtual SVB Securities Global Biopharma Conference from February 13-16, and Johnson will join a panel at the Women’s Health Innovation Series in Boston on February 16 at 3:30 p.m. EST. Daré focuses on advancing innovative products in women’s health, including contraceptives and treatments for sexual health disorders.
Daré Bioscience announced plans to advance DARE-HRT1, an investigational intravaginal ring for treating vasomotor symptoms (VMS) due to menopause, into a single Phase 3 efficacy trial. This product could become the first FDA-approved monthly intravaginal ring delivering both estradiol and progesterone. Positive topline results from prior Phase 1 and Phase 1/2 trials support its potential. The company seeks FDA approval via the 505(b)(2) pathway, leveraging existing data and aiming for a new drug application for women with intact uteri experiencing moderate to severe VMS.
Daré Bioscience (NASDAQ: DARE) recently announced the advancement of DARE-HRT1 into a single Phase 3 clinical trial to treat vasomotor symptoms (VMS) associated with menopause. The investigational intravaginal ring (IVR) is designed to deliver bio-identical hormone therapy. Topline results from the completed Phase 1/2 trial indicate successful delivery of estradiol and progesterone, with significant improvements in VMS and vaginal symptoms reported. The company plans to file a new drug application under the FDA’s 505(b)(2) pathway, with a focus on FDA approval for moderate to severe VMS in women with intact uteri.
Daré Bioscience (NASDAQ: DARE) announced the development of DARE-PDM1, a new product utilizing hydrogel technology for vaginal delivery of diclofenac to treat primary dysmenorrhea. A Phase 1 study is anticipated in 2023, aiming to fill a void in FDA-approved treatments for this condition. The company reported significant progress in 2022, including a licensing agreement with Organon for XACIATO, and several ongoing clinical trials in innovative women's health programs. The global market for dysmenorrhea treatment is projected to grow from USD 11 billion to USD 25 billion by 2028, indicating strong commercial potential.
Daré Bioscience (NASDAQ: DARE) has secured a grant of $584,986 from the Bill & Melinda Gates Foundation to develop a reconstitutable vaginal thermosetting gel for administering live biotherapeutics. This innovative formulation aims to improve vaginal health and could enhance therapeutic availability, especially in diverse climates. The company is addressing the unmet need for products that restore vaginal microbiota post-infection, with the potential to reduce infection recurrence. Daré's first FDA-approved product, XACIATO, is set for commercial sale in early 2023.
Daré Bioscience, Inc. (NASDAQ: DARE) announced positive topline results from its Phase 1/2 clinical study of DARE-VVA1, a novel intravaginal formulation for treating vulvar and vaginal atrophy (VVA) in postmenopausal women, particularly those with hormone receptor-positive breast cancer. The study demonstrated safety and tolerability, with significant improvements in vaginal cytology and bothersome symptoms. DARE-VVA1 could become the first FDA-approved product for VVA in this patient group, addressing a critical unmet need. The study involved 17 participants, with positive outcomes reported across various doses.
Daré Bioscience reported a strong financial position as of September 30, 2022, with $40.4 million in cash. The company received $18 million in non-dilutive cash, bolstering its balance sheet. Key developments include FDA approval for Ovaprene's pivotal study and positive efficacy data for DARE-HRT1. Additionally, subject screening for Sildenafil Cream's Phase 2b RESPOND study has been completed, targeting topline data announcement in Q2 2023. Daré anticipates the first commercial sale of XACIATO in the U.S. in 1H 2023, aimed at addressing bacterial vaginosis affecting 21 million women.
Daré Bioscience, a leader in women’s health innovation, will have its President and CEO, Sabrina Martucci Johnson, present at the Stifel 2022 Healthcare Conference on November 15, 2022, at 9:10 a.m. ET. The presentation will be available via live webcast on the company's website and archived until November 29, 2022. Daré is committed to advancing innovative therapies for women’s health, including FDA-approved products like XACIATO and candidates such as Ovaprene and Sildenafil Cream. For more details, visit their investor relations page.
Daré Bioscience (NASDAQ: DARE) will host a conference call on November 10, 2022, at 4:30 p.m. ET to discuss its Q3 2022 financial results and provide company updates. Interested participants can access the call by dialing (800) 715-9871 for U.S. callers or (646) 307-1963 internationally. The call will also be available via a live webcast on Daré's Investor Relations website. The company focuses on women's health innovations, including its first FDA-approved product, XACIATO, for bacterial vaginosis, and several candidates in clinical development.
FAQ
What is the current stock price of Dare Bioscience (DARE)?
What is the market cap of Dare Bioscience (DARE)?
What is Daré Bioscience's primary focus?
What are Daré Bioscience's key products?
How does Daré Bioscience generate revenue?
What makes Daré Bioscience unique in the biopharmaceutical industry?
Who are Daré Bioscience's key partners?
What is Ovaprene?
What is Sildenafil Cream, 3.6%?
What is Daré Bioscience's strategy for growth?
What challenges does Daré Bioscience face?
What is DARE-HPV?
